Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects

被引：63

作者：

Haïk, S

Brandel, JP

Salomon, D

Sazdovitch, V

Delasnerie-Laupretre, N

Laplanche, JL

Faucheux, BA

Soubrié, C

Boher, E

Belorgey, C

Hauw, JJ

Alpérovitch, A

机构：

[1] Salpetriere Hosp, Raymond Escourolle Neuropathol Lab, INSERM, U360, F-75651 Paris 13, France

[2] Salpetriere Hosp, French Natl Reference Ctr Creutzfeldt Jakob Dis, F-75651 Paris, France

[3] Salpetriere Hosp, Pharmacovigilance Ctr, Pharmacol Lab, F-75651 Paris 13, France

[4] Lariboisiere Hosp, Cent Biochem Lab, Paris, France

[5] AFSSAPS, St Denis, France

来源：

NEUROLOGY | 2004年 / 63卷 / 12期

关键词：

D O I：

10.1212/01.WNL.0000148596.15681.4D

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.

引用

收藏

页码：2413 / 2415

页数：3

相关论文

共 10 条

[1] Evaluation of quinacrine treatment for prion diseases [J].

Barret, A ;

Tagliavini, F ;

Forloni, G ;

Bate, C ;

Salmona, M ;

Colombo, L ;

De Luigi, A ;

Limido, L ;

Suardi, S ;

Rossi, G ;

Auvré, F ;

Adjou, KT ;

Salès, N ;

Williams, A ;

Lasmézas, C ;

Deslys, JP .

JOURNAL OF VIROLOGY, 2003, 77 (15) :8462-8469

[2] Diagnosis of Creutzfeldt-Jakob disease -: Effect of clinical criteria on incidence estimates [J].

Brandel, JP ;

Delasnerie-Lauprêtre, N ;

Laplanche, JL ;

Hauw, JJ ;

Alpérovitch, A .

NEUROLOGY, 2000, 54 (05) :1095-1099

[3] Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model [J].

Collins, SJ ;

Lewis, V ;

Brazier, M ;

Hill, AF ;

Fletcher, A ;

Masters, CL .

ANNALS OF NEUROLOGY, 2002, 52 (04) :503-506

[4] Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation [J].

Doh-Ura, K ;

Iwaki, T ;

Caughey, B .

JOURNAL OF VIROLOGY, 2000, 74 (10) :4894-4897

[5] Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models [J].

Doh-Ura, K ;

Ishikawa, K ;

Murakami-Kubo, I ;

Sasaki, K ;

Mohri, S ;

Race, R ;

Iwaki, T .

JOURNAL OF VIROLOGY, 2004, 78 (10) :4999-5006

[6] Neuropathologic variants of sporadic Creutzfeldt-Jakob disease and codon 129 of PrP gene [J].

Hauw, JJ ;

Sazdovitch, V ;

Laplanche, JL ;

Peoc'h, K ;

Kopp, N ;

Kemeny, J ;

Privat, N ;

Delasnerie-Lauprêtre, N ;

Brandel, JP ;

Deslys, JP ;

Dormont, D ;

Alpérovitch, A .

NEUROLOGY, 2000, 54 (08) :1641-1646

[7] Drugs for malaria and psychosis may offer hope to people with CJD [J].

Josefson, D .

BRITISH MEDICAL JOURNAL, 2001, 323 (7310) :416-416

[8] Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease [J].

Korth, C ;

May, BCH ;

Cohen, FE ;

Prusiner, SB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) :9836-9841

[9] Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease [J].

Scoazec, JY ;

Krolak-Salmon, P ;

Casez, O ;

Besson, G ;

Thobois, S ;

Kopp, N ;

Perret-Liaudet, A ;

Streichenberger, N .

ANNALS OF NEUROLOGY, 2003, 53 (04) :546-547

[10]

*WHO, 2001, REV VAR CREUTZF JAK